The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAssura Regulatory News (AGR)

Share Price Information for Assura (AGR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 41.62
Bid: 41.66
Ask: 41.72
Change: -0.02 (-0.05%)
Spread: 0.06 (0.144%)
Open: 41.60
High: 42.34
Low: 41.38
Prev. Close: 41.64
AGR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

16 Jan 2023 07:00

RNS Number : 7367M
Assura PLC
16 January 2023
 

16 January 2023

Assura plc

 

Trading Update

For the third quarter of the year ending 31 December 2022

 

Assura plc ("Assura"), the leading primary care property investor and developer, today announces its Trading Update for the third quarter of the year to 31 December 2022.

 

Jonathan Murphy, CEO, said:

"Assura has delivered another period of good progress and disciplined activity. Three developments and three asset enhancement projects reached practical completion, providing high-quality new or improved premises for nearly 100,000 patients. Our on-site activities progressed well, with a further 11 developments and seven asset enhancement projects on track to complete in the coming months. This includes initiating our first forward-funding deal in Ireland. 

"We have a strong market position, balance sheet and pipeline of growth opportunities and will continue to deploy capital in a disciplined manner.

"The NHS continues to face tremendous pressure and the need to invest in high-quality primary care to help alleviate this position has never been greater. Assura remains committed to working closely with the NHS to provide crucial primary care infrastructure, while continuing to progress its proven strategy and deliver attractive returns for shareholders."

Disciplined activity during the quarter

· Portfolio of 607 properties with an annualised rent roll of £141.6 million

· Seven additions completed for a total of £47 million: four acquisitions for £11 million and three development completions for £36 million, including the £23 million West Midlands Ambulance Hub

· One development started on site: a €6 million primary care centre in Kilbeggan, our first forward-funding deal in Ireland

· Completed disposal of four properties for £3 million at prices in line with September book values

· Three lease re-gears completed (£0.3 million of existing rent)

· Completed three asset enhancement capital projects (total spend £0.7 million); on site with a further seven (total spend £9.3 million)

· EPC improvement programme continues: nine properties upgraded to EPC B in the quarter, 48% of portfolio now at EPC B or better

 

Development and asset enhancement pipelines provide growth opportunities

· Currently on site with 11 developments; total cost of £121 million (September 2022: 13, £153 million) of which £48 million has been spent to date

· Immediate development pipeline of 10 schemes, where we would normally expect to be on site within 12 months; total cost of £82 million (September 2022: 10, £83 million). We continue to experience some delays to construction timetables and start dates

· 37 lease re-gears covering £8.3 million of existing rent roll in the current pipeline

· Pipeline of 18 capital asset enhancement projects (projected spend £14.3 million) over the next two years

 

Portfolio valuation

· Net initial yield 4.86% at December 2022, an outward movement of 34 basis points since September 2022

· This represents a 7% reduction in portfolio value to £2.7 billion; EPRA NTA approximately 53.6 pence per share at 31 December 2022

 

Strong and sustainable financial position

· At 31 December 2022 net debt stood at £1,122 million with cash and undrawn facilities of £255 million

· All drawn facilities are unsecured with fixed interest (weighted average interest rate of 2.3%) and weighted average maturity 7.25 years

 

 

- ENDS -

 

 

 

 

Assura plc Jayne Cottam, CFO David Purcell, Investor Relations Director

Tel: 01925 945354 Email: Investor@assura.co.uk

 

FGS Global

Gordon SimpsonJames Thompson

 

Tel: 0207 251 3801 Email: Assura@fgsglobal.com

 

This announcement contains inside information as defined in Article 7 of the EU Market Abuse Regulation No 596/2014 and has been announced in accordance with the Company's obligations under Article 17 of that Regulation.

 

Notes to Editors

Assura plc is a national healthcare premises specialist and UK REIT based in Warrington, UK - caring for more than 600 primary healthcare buildings, from which almost seven million patients are served.

 

A constituent of the FTSE 250 and the EPRA* indices, as at 31 December 2022, Assura's portfolio was valued at £2.7 billion.

 

At Assura, we BUILD for health. Assura builds better spaces for people and places, invests in skills and inspires new ways of working, and unlocks the power of design and innovation to deliver lasting impact for communities - aiming for six million people to have benefitted from improvements to and through its healthcare buildings by 2026. 

 

Assura is leading for a sustainable future, targeting net zero carbon across its portfolio by 2040.

 

Further information is available at www.assuraplc.com

 

Assura plc LEI code: 21380026T19N2Y52XF72

 

*EPRA is a registered trademark of the European Public Real Estate Association.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFLFLDLVIVLIV
Date   Source Headline
1st May 20242:30 pmRNSHolding(s) in Company
1st May 20247:00 amRNSNotice of Year End Results
30th Apr 20247:00 amRNSTotal Voting Rights
16th Apr 20247:40 amRNSDirector/PDMR Shareholding
8th Apr 20244:34 pmRNSDirector/PDMR Shareholding
8th Apr 20247:00 amRNSScrip Dividend Declaration
22nd Mar 20242:18 pmRNSHolding(s) in Company
14th Mar 20248:30 amRNSScrip Calculation Price
6th Mar 20241:26 pmRNSDirector/PDMR Shareholding
29th Feb 20247:00 amRNSNotice of Dividend
8th Feb 20242:00 pmRNSCapital Markets Event
7th Feb 20242:33 pmRNSDirector/PDMR Shareholding
1st Feb 20249:32 amRNSTotal Voting Rights
16th Jan 20248:26 amRNSDirector/PDMR Shareholding
10th Jan 20247:00 amRNSTrading Update
9th Jan 20248:59 amRNSDirector/PDMR Shareholding
8th Jan 20247:00 amRNSScrip Dividend Declaration
21st Dec 20234:20 pmRNSDirector/PDMR Shareholding
14th Dec 20237:00 amRNSScrip Calculation Price
6th Dec 20232:57 pmRNSDirector/PDMR Shareholding
30th Nov 20237:00 amRNSNotice of Dividend
16th Nov 20237:00 amRNSAssura Plc Interim Results
8th Nov 20232:32 pmRNSDirector/PDMR Shareholding
1st Nov 20237:00 amRNSAppointment of Board Fellow
31st Oct 20237:00 amRNSNotice of Interim Results
31st Oct 20237:00 amRNSTotal Voting Rights
16th Oct 20232:04 pmRNSDirector/PDMR Shareholding
9th Oct 202311:13 amRNSDirector/PDMR Shareholding
9th Oct 20238:11 amRNSScrip Dividend Declaration
9th Oct 20237:00 amRNSRefinancing of RCF & new sustainability linkage
9th Oct 20237:00 amRNSTrading Update
18th Sep 20239:51 amRNSVesting and sale of restricted shares
14th Sep 20239:20 amRNSScrip Calculation Price
31st Aug 20237:00 amRNSNotice of Dividend
24th Aug 20238:36 amRNSHolding(s) in Company
8th Aug 20235:05 pmRNSDirector/PDMR Shareholding
31st Jul 20239:57 amRNSTotal Voting Rights
24th Jul 20237:00 amRNSDevelopment update
14th Jul 20231:47 pmRNSDirector/PDMR Shareholding
13th Jul 20234:47 pmRNSExercise of Nil Cost Options under PSP
12th Jul 20234:36 pmRNSDirector/PDMR Shareholding
10th Jul 202312:38 pmRNSHolding(s) in Company
10th Jul 20239:20 amRNSHolding(s) in Company
10th Jul 20237:00 amRNSScrip Dividend Declaration & Additional Listing
6th Jul 20232:47 pmRNSResult of AGM
6th Jul 202312:28 pmRNSDirector/PDMR Shareholding
6th Jul 20237:00 amRNSTrading Update
3rd Jul 20237:00 amRNSChange of Registered Office
29th Jun 20234:46 pmRNSHolding(s) in Company
29th Jun 20237:00 amRNSCompletion of 100th development

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.